Volatile Stocks: Intrexon Corp (NYSE:XON), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), Actinium Pharmaceuticals (NYSEMKT:ATNM), Prana Biotechnology (NASDAQ:PRAN), Curis (NASDAQ:CRIS)

Intrexon Corp(NYSE:XON) is working on a slate of projects in a bid to prove that altering DNA can have positive, profit-friendly implications across a variety of industries Intrexon Corp (NYSE:XON) weekly performance is -2.49%. On last trading day company shares ended up $25.03. Analysts mean target price for the company is $32.67. Intrexon Corp (NYSE:XON distance from 50-day simple moving average is 22.24%.

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), announced that the Company will be presenting at the JMP Securities 2014 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Catalyst’s Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 24th at 12:30 pm ET. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares advanced 0.82% in last trading session and ended the day on $2.46. CPRX its return on assets is -64.00%. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) quarterly performance is 7.42%.

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares are being offered by Actinium. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) shares moved down -18.97% in last trading session and was closed at $7.09, while trading in range of $6.93-$7.50. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) year to date performance is 20.37%.

Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm has commenced an investigation Prana Biotechnology Limited (ADR) (NASDAQ:PRAN). The investigation is related to potential violations of federal securities laws and other violations. Prana Biotechnology researches and develops therapeutic drugs for the treatment of neurological disorders. The Company’s product line includes PBT2, which is in Phase II clinical trials for the treatment of Alzheimer’s disease. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) ended the last trading day at $2.07. Company weekly volatility is calculated as 7.49% and price to cash ratio as 5.68. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) showed a negative weekly performance of -1.43%.

Curis, Inc. (Nasdaq: CRIS) announced that it has re-initiated dosing in the single-agent clinical trial of CUDC-427 in patients with advanced and/or refractory solid tumors or lymphomas. CUDC-427 is a novel, oral small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins that support survival of cancer cells. Curis, Inc. (NASDAQ:CRIS) net profit margin is -84.40% and weekly performance is 0.60%. On last trading day company shares ended up $1.69. Analysts mean target price for the company is $5.50. Curis, Inc. (NASDAQ:CRIS) distance from 50-day simple moving average is -13.00%.